Safety Study of Recombinant Vaccine to Prevent ETEC Diarrhea
Information source: U.S. Army Medical Research and Materiel Command
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Escherichia Coli Infection
Intervention: Recombinant fimbrial adhesin dscCfaE (Biological); Recombinant fimbrial adhesin dscCfaE (Biological); Recombinant fimbrial adhesin dscCfaE (Biological); Modified E. coli heat labile enterotoxin LTR192G (Biological)
Phase: Phase 1
Status: Completed
Sponsored by: U.S. Army Medical Research and Materiel Command Official(s) and/or principal investigator(s): Mark S. Riddle, MD, DrPH, Principal Investigator, Affiliation: Naval Medical Research Center
Summary
The purpose of the study is to determine if immunization with a recombinant E. coli protein,
dscCfaE, is safe and immunogenic when administered through the skin using a patch.
Clinical Details
Official title: A Phase 1 Dose-Escalating Study of dscCfaE, Co-Administered With and Without LTR192G, by Transcutaneous Immunization (TCI) in Healthy Adult U.S. Volunteers
Study design: Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Primary outcome: Number of adverse events
Secondary outcome: Number of Seroconversion to LT and dscCfaE; defined as a > 4-fold increase in endpoint titer between pre-and post-vaccination samples.Number of Mucosal responses (fecal IgA); defined as a > 4-fold increase in endpoint titer after adjusting for total IgA. Number of positive IgA-ASC responses; defined as a > 2-fold increase over th e baseline value of the ASC per 10 6 PBMC, when the number of ASC is > 0.5 per 10 6 in the baseline sample
Detailed description:
The purpose of the study is to determine if immunization with dscCfaE with or without a
modified E. coli heat labile enterotoxin, LTR192G, is safe and immunogenic when administered
transcutaneously using a skin wet-patch. If the vaccine is found safe and adequately
immunogenic in humans, a phase 2b vaccination/challenge study would be undertaken to further
evaluate vaccine safety and allow a preliminary assessment of efficacy. With favorable
evidence for safety, immunogenicity, efficacy, complemented by advances in standard
methodology to combine multiple adhesins with an appropriate LT enterotoxoid form, a
multivalent vaccine would be constructed and evaluated for further clinical development.
Eligibility
Minimum age: 18 Years.
Maximum age: 45 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Healthy, adult, male or female, age 18 to 45 years (inclusive) at the time of
enrollment.
- Completion and review of comprehension test (achieved > 70% accuracy).
- Signed informed consent document.
- Available for the required follow-up period and scheduled clinic visits.
- Women: Negative pregnancy test with understanding (through informed consent process)
to not become pregnant during the study or within three (3) months following study
completion.
Exclusion Criteria:
- Health problems such as, chronic medical conditions such as psychiatric conditions,
diabetes mellitus, hypertension or any other conditions that might place the
volunteer at increased risk of adverse events. Study clinicians, in consultation with
the principal investigator (PI), will use clinical judgment on a case-by-case basis
to assess safety risks under this criterion. The PI will consult with the Medical
Monitor as appropriate.
- Clinically significant abnormalities on physical examination.
- Immunosuppressive drugs (use of systemic corticosteroids or chemotherapeutics that
may influence antibody development) or illness (including IgA deficiency).
- Women who are pregnant or planning to become pregnant during the study period plus 3
months beyond the last study safety visit and currently nursing women.
- Participation in research involving another investigational product (defined as
receipt of investigational product or exposure to invasive investigational device) 30
days before planned date of first vaccination or anytime through the last study
safety visit.
- Positive blood test for HBsAg, HCV, HIV-1.
- Clinically significant abnormalities on basic laboratory screening.
- Immunosuppressive illness or IgA deficiency (below the normal limits).
- Exclusionary skin history/findings that would confound assessment or prevent
appropriate local monitoring of adverse events (AEs), or possibly increase the risk
of an AE.
- History of chronic skin disease (clinician judgment).
- History of atopy.
- Acute skin infection/eruptions on the upper arms including fungal infections, severe
acne or active contact dermatitis.
- Allergies that may increase the risk of AEs.
- Regular use (weekly or more often) of antidiarrheal, anti-constipation, or antacid
therapy.
- Abnormal stool pattern (fewer than 3 stools per week or more than 3 stools per day)
on a regular basis; loose or liquid stools on other than an occasional basis.
- History of microbiologically confirmed Enterotoxigenic E. coli (ETEC) or V. cholerae
infection.
- Travel to countries where ETEC or V. cholerae or other enteric infections are endemic
(most of the developing world) within two years prior to dosing (clinician judgment).
- Received previous experimental ETEC or V. cholerae vaccine or live ETEC or V.
cholerae challenge.
- Occupation involving handling of ETEC or V. cholerae currently, or in the past 3
years.
Locations and Contacts
Walter Reed Army Institute of Research Clinical Trial Center, Silver Spring, Maryland 20910, United States
Additional Information
Starting date: July 2011
Last updated: April 24, 2015
|